SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3ui7'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MMT_A_H4BA1426_1 (PHENYLALANINE-4-HYDR OXYLASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 11	VAL A 600 LEU A 623 PHE A 611 LEU A 614 THR A 599	None	1.27A	1mmtA-3ui7A: undetectable	1mmtA-3ui7A: 21.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TBF_A_VIAA501_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 9	TYR A 524 LEU A 635 LEU A 675 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) None C1L A 1 (-4.3A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.58A	1tbfA-3ui7A: 44.4	1tbfA-3ui7A: 38.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 10	TYR A 524 HIS A 525 ALA A 689 GLY A 728 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None None C1L A 1 (-3.5A)	1.27A	1uhoA-3ui7A: 41.3	1uhoA-3ui7A: 39.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 10	TYR A 524 HIS A 525 PHE A 696 GLN A 726 GLY A 728 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) None C1L A 1 (-3.5A)	0.44A	1uhoA-3ui7A: 41.3	1uhoA-3ui7A: 39.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 HIS A 567 LEU A 675 ILE A 692 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.91A	1xlxA-3ui7A: 38.0	1xlxA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 HIS A 567 ILE A 692 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.68A	1xlxB-3ui7A: 38.0	1xlxB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.19A	1xlxB-3ui7A: 38.0	1xlxB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 696 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-3.5A)	0.83A	1xmuA-3ui7A: 38.1	1xmuA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 696 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-3.5A)	1.49A	1xmuA-3ui7A: 38.1	1xmuA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 696	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A)	0.58A	1xmuB-3ui7A: 38.2	1xmuB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 696	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 ( 4.7A)	1.49A	1xmuB-3ui7A: 38.2	1xmuB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	8 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.89A	1xomA-3ui7A: 38.5	1xomA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-3.5A)	1.45A	1xomA-3ui7A: 38.5	1xomA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.26A	1xomA-3ui7A: 38.5	1xomA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-3.5A)	1.47A	1xomB-3ui7A: 38.5	1xomB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 LEU A 675 ILE A 692 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.93A	1xomB-3ui7A: 38.5	1xomB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.25A	1xomB-3ui7A: 38.5	1xomB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.5A)	0.87A	1xoqA-3ui7A: 38.6	1xoqA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-3.5A)	1.44A	1xoqA-3ui7A: 38.6	1xoqA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.5A)	0.90A	1xoqB-3ui7A: 38.5	1xoqB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 LEU A 635 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-3.5A)	1.46A	1xoqB-3ui7A: 38.5	1xoqB-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 ASP A 674 LEU A 675 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.19A	1xosA-3ui7A: 38.3	1xosA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.70A	1xosA-3ui7A: 38.3	1xosA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 LEU A 675 ILE A 692 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.65A	1xotA-3ui7A: 38.2	1xotA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.13A	1xotA-3ui7A: 38.2	1xotA-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 12	TYR A 524 HIS A 525 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.04A	1xotB-3ui7A: 38.4	1xotB-3ui7A: 27.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2C7V_B_MTXB1272_1 (PTERIDINE REDUCTASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	SER A 677 PRO A 523 ASP A 674 MET A 714 GLU A 699	C1L A 1 (-3.6A) None ZN A 772 (-2.4A) None None	1.24A	2c7vB-3ui7A: undetectable	2c7vB-3ui7A: 20.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 11	TYR A 524 HIS A 525 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.47A	2h42A-3ui7A: 40.9	2h42A-3ui7A: 39.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 LEU A 635 LEU A 675 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) None C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.47A	2h42C-3ui7A: 41.2	2h42C-3ui7A: 39.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WEY_A_EV1A1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	12 / 12	TYR A 524 HIS A 525 LEU A 635 LEU A 675 VAL A 678 ILE A 692 TYR A 693 GLU A 695 PHE A 696 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-4.3A) C1L A 1 (-4.9A) C1L A 1 (-4.3A) None None C1L A 1 ( 4.7A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.54A	2weyA-3ui7A: 50.9	2weyA-3ui7A: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WEY_B_EV1B1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	8 / 8	LEU A 635 VAL A 678 ILE A 692 TYR A 693 PHE A 696 MET A 713 GLN A 726 PHE A 729	None C1L A 1 (-4.9A) C1L A 1 (-4.3A) None C1L A 1 ( 4.7A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.45A	2weyB-3ui7A: 49.6	2weyB-3ui7A: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2XNR_A_ACTA1001_0 (NUCLEAR POLYADENYLATED RNA-BINDING PROTEIN 3)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	SER A 497 ARG A 496 GLN A 542	None	0.99A	2xnrA-3ui7A: undetectable	2xnrA-3ui7A: 14.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZZA_A_FOLA164_0 (DIHYDROFOLATE REDUCTASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	MET A 669 GLU A 552 ILE A 744 LEU A 654 THR A 549	None	1.30A	2zzaA-3ui7A: undetectable	2zzaA-3ui7A: 19.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZZA_B_FOLB164_0 (DIHYDROFOLATE REDUCTASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 11	MET A 669 GLU A 552 ILE A 744 LEU A 654 THR A 549	None	1.24A	2zzaB-3ui7A: undetectable	2zzaB-3ui7A: 19.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3B2R_A_VDNA1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 LEU A 675 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.69A	3b2rA-3ui7A: 36.5	3b2rA-3ui7A: 40.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3B2R_B_VDNB1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 11	TYR A 524 HIS A 525 LEU A 675 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-4.3A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.54A	3b2rB-3ui7A: 36.2	3b2rB-3ui7A: 40.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_A_ROFA901_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	ASP A 674 LEU A 675 GLN A 726	ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-2.9A)	0.41A	3g4lA-3ui7A: 38.0	3g4lA-3ui7A: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_B_ROFB902_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.5A)	0.83A	3g4lB-3ui7A: 38.2	3g4lB-3ui7A: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_C_ROFC903_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A)	0.59A	3g4lC-3ui7A: 38.0	3g4lC-3ui7A: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	TYR A 524 HIS A 525 ASP A 674 LEU A 675 ILE A 692 GLN A 726	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) ZN A 772 (-2.4A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-2.9A)	0.75A	3g4lD-3ui7A: 38.3	3g4lD-3ui7A: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 9	TYR A 524 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.16A	3iakA-3ui7A: 37.8	3iakA-3ui7A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 9	TYR A 524 ILE A 692 PHE A 696 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.74A	3iakA-3ui7A: 37.8	3iakA-3ui7A: 28.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 9	TYR A 524 HIS A 525 LEU A 635 MET A 713 GLN A 726 PHE A 729 VAL A 733	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A) None	0.60A	3jwqA-3ui7A: 44.3	3jwqA-3ui7A: 42.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_B_VIAB901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 11	TYR A 524 HIS A 525 LEU A 635 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.77A	3jwqB-3ui7A: 44.0 3jwqC-3ui7A: 44.0	3jwqB-3ui7A: 42.11 3jwqC-3ui7A: 42.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 7	TYR A 524 HIS A 525 MET A 713 GLN A 726 PHE A 729 VAL A 733	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A) None	0.57A	3jwqC-3ui7A: 44.0	3jwqC-3ui7A: 42.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	7 / 11	TYR A 524 HIS A 525 LEU A 635 PHE A 696 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.1A) None C1L A 1 ( 4.7A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	0.69A	3jwqA-3ui7A: 44.3 3jwqD-3ui7A: 43.8	3jwqA-3ui7A: 42.11 3jwqD-3ui7A: 42.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3S8P_B_SAMB500_1 (HISTONE-LYSINE N-METHYLTRANSFERASE SUV420H1)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	HIS A 535 SER A 497 ASN A 543	None	0.84A	3s8pB-3ui7A: 1.2	3s8pB-3ui7A: 18.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3T3R_B_9PLB501_1 (CYTOCHROME P450 2A6)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 9	PHE A 490 VAL A 494 PHE A 611 ILE A 558 GLY A 555	None	1.27A	3t3rB-3ui7A: undetectable	3t3rB-3ui7A: 21.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3T3R_C_9PLC501_1 (CYTOCHROME P450 2A6)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 9	PHE A 490 VAL A 494 PHE A 611 ILE A 558 GLY A 555	None	1.34A	3t3rC-3ui7A: undetectable	3t3rC-3ui7A: 21.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3T3R_D_9PLD501_1 (CYTOCHROME P450 2A6)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 10	PHE A 490 VAL A 494 PHE A 611 ILE A 558 GLY A 555	None	1.33A	3t3rD-3ui7A: undetectable	3t3rD-3ui7A: 21.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 9	TYR A 524 LEU A 675 ILE A 692 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 (-4.3A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.04A	3tvxA-3ui7A: 38.5	3tvxA-3ui7A: 28.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 7	TYR A 524 ILE A 692 PHE A 696 MET A 713 GLN A 726 PHE A 729	C1L A 1 ( 4.8A) C1L A 1 (-4.3A) C1L A 1 ( 4.7A) C1L A 1 (-3.7A) C1L A 1 (-2.9A) C1L A 1 (-3.5A)	1.03A	3tvxB-3ui7A: 38.3	3tvxB-3ui7A: 28.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WRK_A_CAMA502_0 (CAMPHOR 5-MONOOXYGENASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 5	PHE A 477 LEU A 464 GLY A 488 ILE A 479 VAL A 531	None	1.45A	3wrkA-3ui7A: undetectable	3wrkA-3ui7A: 20.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AFG_C_QMRC1214_1 (CAPITELLA TELETA ACHBP)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	4 / 8	VAL A 491 TYR A 538 ILE A 512 ILE A 489	None	0.96A	4afgD-3ui7A: undetectable 4afgE-3ui7A: undetectable	4afgD-3ui7A: 19.24 4afgE-3ui7A: 19.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4BBO_B_ACTB1114_0 (BLR5658 PROTEIN)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	TRP A 762 TRP A 682 THR A 685	None	1.26A	4bboB-3ui7A: undetectable	4bboB-3ui7A: 15.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4CEV_C_GAIC409_0 (PROTEIN (ARGINASE))	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	4 / 6	ASP A 566 ARG A 520 HIS A 567 LEU A 582	None	1.35A	4cevA-3ui7A: undetectable 4cevC-3ui7A: undetectable	4cevA-3ui7A: 20.17 4cevC-3ui7A: 20.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4DM8_B_REAB1501_1 (RETINOIC ACID RECEPTOR BETA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	5 / 12	ALA A 672 LEU A 745 LEU A 741 ILE A 744 LEU A 556	None	1.10A	4dm8B-3ui7A: undetectable	4dm8B-3ui7A: 21.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4PEV_A_ADNA501_2 (MEMBRANE LIPOPROTEIN FAMILY PROTEIN)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	PRO A 465 LEU A 464 HIS A 535	None	0.68A	4pevA-3ui7A: undetectable	4pevA-3ui7A: 22.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4W5N_A_IPHA903_0 (PROTEIN ARGONAUTE-2)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	4 / 4	TYR A 638 THR A 671 GLY A 667 LEU A 645	None	1.04A	4w5nA-3ui7A: undetectable	4w5nA-3ui7A: 16.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CPR_B_SAMB402_1 (HISTONE-LYSINE N-METHYLTRANSFERASE SUV420H1)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	HIS A 535 SER A 497 ASN A 543	None	0.87A	5cprB-3ui7A: 1.4	5cprB-3ui7A: 19.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OEX_A_CUA604_0 (THIOCYANATE DEHYDROGENASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	HIS A 529 HIS A 525 HIS A 567	ZN A 772 (-3.5A) C1L A 1 (-4.1A) None	1.01A	5oexA-3ui7A: undetectable	5oexA-3ui7A: 19.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6A5Z_L_9CRL501_0 (RETINOIC ACID RECEPTOR RXR-ALPHA)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	6 / 12	ILE A 540 ALA A 539 GLN A 542 LEU A 541 CYH A 676 LEU A 751	None	1.49A	6a5zL-3ui7A: undetectable	6a5zL-3ui7A: 11.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BP4_A_SAMA505_1 (HISTONE-LYSINE N-METHYLTRANSFERASE, H3 LYSINE-9 SPECIFIC)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	3 / 3	ILE A 766 ASN A 731 CYH A 755	None	0.82A	6bp4A-3ui7A: undetectable	6bp4A-3ui7A: 21.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6F6J_A_ACTA404_0 (L-LYSINE 3-HYDROXYLASE)	3ui7	CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A (Homo sapiens)	4 / 6	ILE A 744 LEU A 547 VAL A 665 ARG A 662	None	0.98A	6f6jA-3ui7A: undetectable	6f6jA-3ui7A: undetectable

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1MMT_A_H4BA1426_1","PHENYLALANINE-4-HYDROXYLASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"VAL A 600;LEU A 623;PHE A 611;LEU A 614;THR A 599","None","1.27A","1mmtA-3ui7A:undetectable","1mmtA-3ui7A:21.04"],["1TBF_A_VIAA501_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;LEU A 635;LEU A 675;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);None;C1L A   1 (-4.3A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.58A","1tbfA-3ui7A:44.4","1tbfA-3ui7A:38.53"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;ALA A 689;GLY A 728;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;None;C1L A   1 (-3.5A)","1.27A","1uhoA-3ui7A:41.3","1uhoA-3ui7A:39.23"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;PHE A 696;GLN A 726;GLY A 728;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);None;C1L A   1 (-3.5A)","0.44A","1uhoA-3ui7A:41.3","1uhoA-3ui7A:39.23"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;HIS A 567;LEU A 675;ILE A 692;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.91A","1xlxA-3ui7A:38.0","1xlxA-3ui7A:27.10"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;HIS A 567;ILE A 692;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.68A","1xlxB-3ui7A:38.0","1xlxB-3ui7A:27.10"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.19A","1xlxB-3ui7A:38.0","1xlxB-3ui7A:27.10"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 696;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-3.5A)","0.83A","1xmuA-3ui7A:38.1","1xmuA-3ui7A:27.10"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 696;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-3.5A)","1.49A","1xmuA-3ui7A:38.1","1xmuA-3ui7A:27.10"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 696","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A)","0.58A","1xmuB-3ui7A:38.2","1xmuB-3ui7A:27.10"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 696","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 ( 4.7A)","1.49A","1xmuB-3ui7A:38.2","1xmuB-3ui7A:27.10"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",8,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.89A","1xomA-3ui7A:38.5","1xomA-3ui7A:28.53"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-3.5A)","1.45A","1xomA-3ui7A:38.5","1xomA-3ui7A:28.53"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.26A","1xomA-3ui7A:38.5","1xomA-3ui7A:28.53"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-3.5A)","1.47A","1xomB-3ui7A:38.5","1xomB-3ui7A:28.53"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;LEU A 675;ILE A 692;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.93A","1xomB-3ui7A:38.5","1xomB-3ui7A:28.53"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.25A","1xomB-3ui7A:38.5","1xomB-3ui7A:28.53"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.5A)","0.87A","1xoqA-3ui7A:38.6","1xoqA-3ui7A:28.53"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-3.5A)","1.44A","1xoqA-3ui7A:38.6","1xoqA-3ui7A:28.53"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.5A)","0.90A","1xoqB-3ui7A:38.5","1xoqB-3ui7A:28.53"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 635;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-3.5A)","1.46A","1xoqB-3ui7A:38.5","1xoqB-3ui7A:28.53"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;ASP A 674;LEU A 675;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.19A","1xosA-3ui7A:38.3","1xosA-3ui7A:27.10"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.70A","1xosA-3ui7A:38.3","1xosA-3ui7A:27.10"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;LEU A 675;ILE A 692;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.65A","1xotA-3ui7A:38.2","1xotA-3ui7A:27.10"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.13A","1xotA-3ui7A:38.2","1xotA-3ui7A:27.10"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.04A","1xotB-3ui7A:38.4","1xotB-3ui7A:27.10"],["2C7V_B_MTXB1272_1","PTERIDINE REDUCTASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"SER A 677;PRO A 523;ASP A 674;MET A 714;GLU A 699","C1L A   1 (-3.6A);None; ZN A 772 (-2.4A);None;None","1.24A","2c7vB-3ui7A:undetectable","2c7vB-3ui7A:20.52"],["2H42_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.47A","2h42A-3ui7A:40.9","2h42A-3ui7A:39.77"],["2H42_C_VIAC903_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 635;LEU A 675;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);None;C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.47A","2h42C-3ui7A:41.2","2h42C-3ui7A:39.77"],["2WEY_A_EV1A1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",12,"TYR A 524;HIS A 525;LEU A 635;LEU A 675;VAL A 678;ILE A 692;TYR A 693;GLU A 695;PHE A 696;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-4.3A);C1L A   1 (-4.9A);C1L A   1 (-4.3A);None;None;C1L A   1 ( 4.7A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.54A","2weyA-3ui7A:50.9","2weyA-3ui7A:100.00"],["2WEY_B_EV1B1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",8,"LEU A 635;VAL A 678;ILE A 692;TYR A 693;PHE A 696;MET A 713;GLN A 726;PHE A 729","None;C1L A   1 (-4.9A);C1L A   1 (-4.3A);None;C1L A   1 ( 4.7A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.45A","2weyB-3ui7A:49.6","2weyB-3ui7A:100.00"],["2XNR_A_ACTA1001_0","NUCLEAR POLYADENYLATED RNA-BINDING PROTEIN 3","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"SER A 497;ARG A 496;GLN A 542","None","0.99A","2xnrA-3ui7A:undetectable","2xnrA-3ui7A:14.38"],["2ZZA_A_FOLA164_0","DIHYDROFOLATE REDUCTASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"MET A 669;GLU A 552;ILE A 744;LEU A 654;THR A 549","None","1.30A","2zzaA-3ui7A:undetectable","2zzaA-3ui7A:19.09"],["2ZZA_B_FOLB164_0","DIHYDROFOLATE REDUCTASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"MET A 669;GLU A 552;ILE A 744;LEU A 654;THR A 549","None","1.24A","2zzaB-3ui7A:undetectable","2zzaB-3ui7A:19.09"],["3B2R_A_VDNA1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;LEU A 675;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.69A","3b2rA-3ui7A:36.5","3b2rA-3ui7A:40.64"],["3B2R_B_VDNB1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;LEU A 675;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-4.3A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.54A","3b2rB-3ui7A:36.2","3b2rB-3ui7A:40.64"],["3G4L_A_ROFA901_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"ASP A 674;LEU A 675;GLN A 726"," ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-2.9A)","0.41A","3g4lA-3ui7A:38.0","3g4lA-3ui7A:27.92"],["3G4L_B_ROFB902_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.5A)","0.83A","3g4lB-3ui7A:38.2","3g4lB-3ui7A:27.92"],["3G4L_C_ROFC903_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A)","0.59A","3g4lC-3ui7A:38.0","3g4lC-3ui7A:27.92"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;ASP A 674;LEU A 675;ILE A 692;GLN A 726","C1L A   1 ( 4.8A);C1L A   1 (-4.1A); ZN A 772 (-2.4A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-2.9A)","0.75A","3g4lD-3ui7A:38.3","3g4lD-3ui7A:27.92"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.16A","3iakA-3ui7A:37.8","3iakA-3ui7A:28.53"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"TYR A 524;ILE A 692;PHE A 696;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.74A","3iakA-3ui7A:37.8","3iakA-3ui7A:28.53"],["3JWQ_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;LEU A 635;MET A 713;GLN A 726;PHE A 729;VAL A 733","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A);None","0.60A","3jwqA-3ui7A:44.3","3jwqA-3ui7A:42.11"],["3JWQ_B_VIAB901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;LEU A 635;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.77A","3jwqB-3ui7A:44.0;3jwqC-3ui7A:44.0","3jwqB-3ui7A:42.11;3jwqC-3ui7A:42.11"],["3JWQ_C_VIAC901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;HIS A 525;MET A 713;GLN A 726;PHE A 729;VAL A 733","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A);None","0.57A","3jwqC-3ui7A:44.0","3jwqC-3ui7A:42.11"],["3JWQ_D_VIAD901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",7,"TYR A 524;HIS A 525;LEU A 635;PHE A 696;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.1A);None;C1L A   1 ( 4.7A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","0.69A","3jwqA-3ui7A:44.3;3jwqD-3ui7A:43.8","3jwqA-3ui7A:42.11;3jwqD-3ui7A:42.11"],["3S8P_B_SAMB500_1","HISTONE-LYSINE N-METHYLTRANSFERASE SUV420H1","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"HIS A 535;SER A 497;ASN A 543","None","0.84A","3s8pB-3ui7A:1.2","3s8pB-3ui7A:18.95"],["3T3R_B_9PLB501_1","CYTOCHROME P450 2A6","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"PHE A 490;VAL A 494;PHE A 611;ILE A 558;GLY A 555","None","1.27A","3t3rB-3ui7A:undetectable","3t3rB-3ui7A:21.33"],["3T3R_C_9PLC501_1","CYTOCHROME P450 2A6","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"PHE A 490;VAL A 494;PHE A 611;ILE A 558;GLY A 555","None","1.34A","3t3rC-3ui7A:undetectable","3t3rC-3ui7A:21.33"],["3T3R_D_9PLD501_1","CYTOCHROME P450 2A6","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"PHE A 490;VAL A 494;PHE A 611;ILE A 558;GLY A 555","None","1.33A","3t3rD-3ui7A:undetectable","3t3rD-3ui7A:21.33"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;LEU A 675;ILE A 692;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 (-4.3A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.04A","3tvxA-3ui7A:38.5","3tvxA-3ui7A:28.73"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"TYR A 524;ILE A 692;PHE A 696;MET A 713;GLN A 726;PHE A 729","C1L A   1 ( 4.8A);C1L A   1 (-4.3A);C1L A   1 ( 4.7A);C1L A   1 (-3.7A);C1L A   1 (-2.9A);C1L A   1 (-3.5A)","1.03A","3tvxB-3ui7A:38.3","3tvxB-3ui7A:28.73"],["3WRK_A_CAMA502_0","CAMPHOR 5-MONOOXYGENASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"PHE A 477;LEU A 464;GLY A 488;ILE A 479;VAL A 531","None","1.45A","3wrkA-3ui7A:undetectable","3wrkA-3ui7A:20.24"],["4AFG_C_QMRC1214_1","CAPITELLA TELETA ACHBP;CAPITELLA TELETA ACHBP;CAPITELLA TELETA ACHBP","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",4,"VAL A 491;TYR A 538;ILE A 512;ILE A 489","None","0.96A","4afgD-3ui7A:undetectable;4afgE-3ui7A:undetectable","4afgD-3ui7A:19.24;4afgE-3ui7A:19.24"],["4BBO_B_ACTB1114_0","BLR5658 PROTEIN","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"TRP A 762;TRP A 682;THR A 685","None","1.26A","4bboB-3ui7A:undetectable","4bboB-3ui7A:15.12"],["4CEV_C_GAIC409_0","PROTEIN (ARGINASE)","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",4,"ASP A 566;ARG A 520;HIS A 567;LEU A 582","None","1.35A","4cevA-3ui7A:undetectable;4cevC-3ui7A:undetectable","4cevA-3ui7A:20.17;4cevC-3ui7A:20.17"],["4DM8_B_REAB1501_1","RETINOIC ACID RECEPTOR BETA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",5,"ALA A 672;LEU A 745;LEU A 741;ILE A 744;LEU A 556","None","1.10A","4dm8B-3ui7A:undetectable","4dm8B-3ui7A:21.26"],["4PEV_A_ADNA501_2","MEMBRANE LIPOPROTEIN FAMILY PROTEIN","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"PRO A 465;LEU A 464;HIS A 535","None","0.68A","4pevA-3ui7A:undetectable","4pevA-3ui7A:22.25"],["4W5N_A_IPHA903_0","PROTEIN ARGONAUTE-2","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",4,"TYR A 638;THR A 671;GLY A 667;LEU A 645","None","1.04A","4w5nA-3ui7A:undetectable","4w5nA-3ui7A:16.67"],["5CPR_B_SAMB402_1","HISTONE-LYSINE N-METHYLTRANSFERASE SUV420H1","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"HIS A 535;SER A 497;ASN A 543","None","0.87A","5cprB-3ui7A:1.4","5cprB-3ui7A:19.53"],["5OEX_A_CUA604_0","THIOCYANATE DEHYDROGENASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"HIS A 529;HIS A 525;HIS A 567"," ZN A 772 (-3.5A);C1L A   1 (-4.1A);None","1.01A","5oexA-3ui7A:undetectable","5oexA-3ui7A:19.71"],["6A5Z_L_9CRL501_0","RETINOIC ACID RECEPTOR RXR-ALPHA","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",6,"ILE A 540;ALA A 539;GLN A 542;LEU A 541;CYH A 676;LEU A 751","None","1.49A","6a5zL-3ui7A:undetectable","6a5zL-3ui7A:11.04"],["6BP4_A_SAMA505_1","HISTONE-LYSINE N-METHYLTRANSFERASE, H3 LYSINE-9 SPECIFIC","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",3,"ILE A 766;ASN A 731;CYH A 755","None","0.82A","6bp4A-3ui7A:undetectable","6bp4A-3ui7A:21.37"],["6F6J_A_ACTA404_0","L-LYSINE 3-HYDROXYLASE","3ui7","CAMP AND CAMP-INHIBITED CGMP 3',5'-CYCLIC PHOSPHODIESTERASE 10A","Homo sapiens",4,"ILE A 744;LEU A 547;VAL A 665;ARG A 662","None","0.98A","6f6jA-3ui7A:undetectable","6f6jA-3ui7A:undetectable"]]